Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Big Pharma Holds Steady With One-Third Of Novel Agents Approved In US In 2020

Feb 10 2021

• By Bridget Silverman

blocks — HOW DO THE BIGGEST FIRMS STACK UP IN NOVEL APPROVALS?

Related Content

US FDA 2020 Novel Approval Count Rises To 53 At CDER, Plus 5 New CBER Biologics

Jan 01 2021

Can We Talk? US FDA Remote Records Review Missteps Worry Industry

Nov 19 2020

Is Bristol’s Long-Term Revenue Growth A Potential Salve For Celgene Shareholders?

Jan 12 2021

Aducanumab Approval Decision Delayed: Could This Be Good News?

Jan 29 2021

Pfizer Gains New Commercial Drug Orgovyx In Deal With Myovant

Dec 28 2020

Galapagos CEO Upbeat Despite Filgotinib Upset In US

Dec 24 2020

Gilead Buys Pipeline-In-A-Product With $21bn Immunomedics Deal

Sep 14 2020

Roche Backs Blueprint's Precision Therapy Pralsetinib To Challenge Lilly

Jul 14 2020

Related Companies

Novartis AG

Pfizer Inc.

Gilead Sciences, Inc.

Roche Holding AG

Immunomedics, Inc.

Galapagos NV

Chugai Pharmaceutical Co., Ltd.

PTC Therapeutics, Inc.

Blueprint Medicines Corporation

Eli Lilly and Company

Sanofi

Recordati Ilac

Avid Radiopharmaceuticals Inc.

Sanofi Pasteur

Incyte Corporation

MorphoSys AG

Acacia Pharma Group plc

Myovant Sciences Ltd.

Loxo Oncology at Lilly

The Medicines Company

Alkermes plc

Molecular Partners AG

Additional Topics

Approvals Companies Complete Response Letters Innovation FDA Drug Review Regulation BioPharmaceutical

More from Innovation

More from In Vivo

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window